中国临床实用医学
中國臨床實用醫學
중국림상실용의학
CHINA CLINICAL PRACTICAL MEDICINE
2010年
2期
63-64
,共2页
胡学军%欧庆连%梁雪琼%聂冰
鬍學軍%歐慶連%樑雪瓊%聶冰
호학군%구경련%량설경%섭빙
系统性红斑狼疮%死亡原因
繫統性紅斑狼瘡%死亡原因
계통성홍반랑창%사망원인
Systemic Lupus Erythematosus%Cause of death
目的 分析系统性红斑狼疮(SLE)患者的死亡原因及相关因素,探讨降低死亡率的方法.方法 对31例住院死亡的SLE病例进行回顾性分析,并分析死亡原因与临床相关因素的关系.结果 该组病例死亡率为9.7%,死于SLE引起的器官受累26例(83.9%),死于感染的有5例(16.1%).与该组病例死亡相关的临床因素有:部分病例长期误诊;部分患者未能根据病情及时调整免疫抑制治疗;患者的依从性差等因素.结论 本组病例的死亡原因仍以SLE引起的器官损伤为主,原因为疫抑制治疗相对保守.早期诊断、及时合理免疫抑制治疗、积极的患者宣教以增强患者的治疗依从性,能提高SLE生存率.
目的 分析繫統性紅斑狼瘡(SLE)患者的死亡原因及相關因素,探討降低死亡率的方法.方法 對31例住院死亡的SLE病例進行迴顧性分析,併分析死亡原因與臨床相關因素的關繫.結果 該組病例死亡率為9.7%,死于SLE引起的器官受纍26例(83.9%),死于感染的有5例(16.1%).與該組病例死亡相關的臨床因素有:部分病例長期誤診;部分患者未能根據病情及時調整免疫抑製治療;患者的依從性差等因素.結論 本組病例的死亡原因仍以SLE引起的器官損傷為主,原因為疫抑製治療相對保守.早期診斷、及時閤理免疫抑製治療、積極的患者宣教以增彊患者的治療依從性,能提高SLE生存率.
목적 분석계통성홍반랑창(SLE)환자적사망원인급상관인소,탐토강저사망솔적방법.방법 대31례주원사망적SLE병례진행회고성분석,병분석사망원인여림상상관인소적관계.결과 해조병례사망솔위9.7%,사우SLE인기적기관수루26례(83.9%),사우감염적유5례(16.1%).여해조병례사망상관적림상인소유:부분병례장기오진;부분환자미능근거병정급시조정면역억제치료;환자적의종성차등인소.결론 본조병례적사망원인잉이SLE인기적기관손상위주,원인위역억제치료상대보수.조기진단、급시합리면역억제치료、적겁적환자선교이증강환자적치료의종성,능제고SLE생존솔.
Objective To analyze the cause of death and related factors of death of SLE,to explore the method of reducing mortality rate. Methods 31 death cases of hospitalized patients with SLE were analyzed retrospectively, and investigated the relations between the causes of death and clinical related factors. Results The mortality rate of patients in this group was 9.7% ,26 cases( 83.9% )were dead of organ lesion which was caused by SLE ,5 cases( 16.1% )were dead of infection. The clinical related factors for the death of these patients were long time diagnostic errors, failing to promptly adjust the immunosuppressive therapy according to the disease,poor treatment compliance etc. Conclusion The main cause of death of patients in this group is still the organ lesion caused by SLE, the reason is immunosuppressive therapy relatively conservative. Early diagnosis, timely and reasonable immunosuppressive therapy, positive patients education and enhancing patient's treatment compliance can improve the survival rate of SLE.